{"id":720624,"date":"2026-06-07T07:55:38","date_gmt":"2026-06-07T07:55:38","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/720624\/"},"modified":"2026-06-07T07:55:38","modified_gmt":"2026-06-07T07:55:38","slug":"regeneron-regn-says-ema-accepted-review-for-otarmeni-application","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/720624\/","title":{"rendered":"Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application"},"content":{"rendered":"\n

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Debt-Free S&P 500 Stocks to Buy Now<\/a>.<\/p>\n

On May 22, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the European Medicines Agency accepted for review under Accelerated Assessment the Marketing Authorization Application for Otarmeni, an in vivo adeno-associated virus vector-based gene therapy for biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni would become the first gene therapy for OTOF-related hearing loss in the European Union. The application is supported by data from the pivotal CHORD trial, where 24 participants received a single dose of Otarmeni through intracochlear infusion.<\/p>\n

On May 19, 2026, Canaccord analyst John Newman lowered the firm\u2019s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $875 from $1,057 and maintained a Buy rating on the shares. Newman updated the model after the Phase 3 study of fianlimab+cemiplimab versus pembrolizumab failed to hit statistical significance on the primary endpoint of progression-free survival, calling it a surprising and disappointing event.<\/p>\n

\"Regeneron Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application <\/p>\n

Wolfe Research analyst Alexandria Hammond also lowered the firm\u2019s price target on Regeneron to $860 from $900 and maintained an Outperform rating. Hammond said the company\u2019s LAG-3 trial missed its primary endpoint, while noting that commercial execution will be important and that second-half 2026 catalysts may be underappreciated.<\/p>\n

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) discovers, develops, manufactures, and commercializes medicines to treat various diseases worldwide.<\/p>\n

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/a>.<\/p>\n

READ NEXT:\u00a033 Stocks That Should Double in 3 Years<\/a> and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy<\/a>.\u00a0<\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Debt-Free S&P 500 Stocks to Buy Now. On…\n","protected":false},"author":2,"featured_media":720625,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[349353,64,63,190461,2588,5278,137,349352,349351,490,349350],"class_list":["post-720624","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-alexandria-hammond","tag-au","tag-australia","tag-european-medicines-agency","tag-european-union","tag-gene-therapy","tag-health","tag-john-newman","tag-marketing-authorization-application","tag-medication","tag-regeneron-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/720624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=720624"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/720624\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/720625"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=720624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=720624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=720624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}